此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

Incidental Thyroid Cancer in Cases With Inflammatory Thyroid Lesion (Thyroid cancer)

2026年8月10日 更新者：Abdelrahman Mohamed Salah、Minia University

Incidental Thyroid Cancer in Patients With Inflammatory Thyroid Lesions: A Cohort Study From a Tertiary Care Center

This study aim to assess for the incidence of thyroid cancer in patients with autoimmune thyroiditis (Inflammatory thyroid Lesions)

研究概览

地位

完全的

条件

干预/治疗

详细说明

The relationship between chronic inflammation and carcinogenesis is well established in multiple organ systems, including the liver, stomach, and colon. In the thyroid, chronic lymphocytic infiltration may create a pro-inflammatory microenvironment that promotes cellular proliferation, DNA damage, and oncogenic transformation. Several studies have suggested an increased risk of thyroid cancer, particularly papillary thyroid carcinoma (PTC), in patients with Hashimoto thyroiditis

研究类型

介入性

注册 (实际的)

98

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 埃及
    • Minya Governorate
      • Minya、Minya Governorate、埃及、61611
        • Faculty of Medicine

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

不

描述

Inclusion Criteria:

  1. All types of autoimmune thyroiditis, including:

    • Graves' disease
    • Toxic multinodular goiter (TMNG)
    • Toxic nodule (TN)
    • Hashimoto thyroiditis
    • Unspecified toxic nodular goiter
  2. Age between 18 and 60 years
  3. Underwent thyroid surgical operation (lobectomy or total thyroidectomy)

Exclusion Criteria:

  1. Patients with known differentiated thyroid cancer before surgery
  2. Recurrent thyroid disease (previous thyroid surgery)
  3. Patients unfit for operation (American Society of Anesthesiologists grade IV or V)
  4. Incomplete histopathological data
  5. Patients with medullary thyroid carcinoma or anaplastic thyroid cancer

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：其他
  • 分配：不适用
  • 介入模型：单组作业
  • 屏蔽：无（打开标签）

武器和干预

参与者组/臂
干预/治疗
其他：Inflammatory thyroid lesions
The presence of thyroiditis was determined considering histological diagnosis taken post-surgery, and we considered the correlation between any presence of thyroiditis and all Differentiated thyroid cancer, taken from the histopathological examination after pathologic analysis.
其他：total thyroidectomy
Diagnosis of differentiated thyroid cancer: The presence of thyroid cancer was determined based on histopathological examination of the resected specimen

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
• Incidence of incidental differentiated thyroid cancer with autoimmune thyroiditis
大体时间：At time of surgery (postoperative histopathology)

Title: Incidence of incidental differentiated thyroid cancer

Unit of measure: % of patients (proportion)

Metric/method: Histopathological examination of surgical specimen
At time of surgery (postoperative histopathology)

次要结果测量

结果测量
措施说明
大体时间
Incidence of incidental differentiated thyroid cancer by autoimmune thyroiditis subtype
大体时间：At time of surgery

Unit of Measure

Percentage of patients within each subtype (Hashimoto thyroiditis, Graves' disease, toxic nodular goiter)

Metric / Method

Histopathological classification of thyroiditis subtype and cancer diagnosis; comparison using Chi-square test or Fisher's exact test
At time of surgery
Outcome 3A: Age comparison
大体时间：At time of surgery
Outcome Measure Title Mean age difference between patients with and without incidental differentiated thyroid cancer Unit of Measure Years (mean ± standard deviation) Metric / Method Unpaired Student's t-test or Mann-Whitney U test
At time of surgery
Outcome 3B: Sex distribution
大体时间：Preoperative (within 30 days before surgery)
Field Entry Outcome Measure Title Proportion of patients with positive anti-thyroid peroxidase (anti-TPO) antibodies who have incidental differentiated thyroid cancer Unit of Measure Percentage of patients Metric / Method Serological testing (anti-TPO antibodies measured by immunoassay); Chi-square test or logistic regression for association
Preoperative (within 30 days before surgery)
Secondary Outcome 4 - Tumor characteristics Outcome 4A: Tumor size
大体时间：At time of surgery
Outcome Measure Title Maximum tumor diameter in incidental differentiated thyroid cancers Unit of Measure Centimeters (mean ± standard deviation and range) Metric / Method Pathological measurement of surgical specimen
At time of surgery
Outcome 4B: Microcarcinoma proportion
大体时间：At time of surgery
Outcome Measure Title Proportion of incidental thyroid cancers that are microcarcinomas (≤1 cm) Unit of Measure Percentage of patients with incidental cancer Metric / Method Pathological measurement; defined as tumor size ≤1 cm
At time of surgery
Outcome 4C: Lymph node metastasis
大体时间：At time of surgery
Outcome Measure Title Proportion of patients with incidental differentiated thyroid cancer who have lymph node metastasis Unit of Measure Percentage of patients with incidental cancer Metric / Method Histopathological examination of central neck dissection specimens
At time of surgery
Outcome 4D: Multifocality
大体时间：At time of surgery
Outcome Measure Title Proportion of patients with incidental differentiated thyroid cancer who have multifocal disease Unit of Measure Percentage of patients with incidental cancer Metric / Method Histopathological examination (two or more distinct tumor foci)
At time of surgery
Outcome 3E: Extrathyroidal extension
大体时间：At time of surgery
Outcome Measure Title Proportion of patients with incidental differentiated thyroid cancer who have extrathyroidal extension Unit of Measure Percentage of patients with incidental cancer Metric / Method Histopathological examination (minimal or extensive extension)
At time of surgery

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Minia University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年2月1日

初级完成 (实际的)

2026年2月1日

研究完成 (实际的)

2026年5月31日

研究注册日期

首次提交

2026年6月6日

首先提交符合 QC 标准的

2026年6月11日

首次发布 (实际的)

2026年6月17日

研究记录更新

最后更新发布 (实际的)

2026年8月11日

上次提交的符合 QC 标准的更新

2026年8月10日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • 1462/02/2025

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

是的

IPD 计划说明

The data will be available upon a reasonable request from the corresponding author.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅